In agreement with a recent study in TP53-mutated AML[46], most of these focal deletions affect known AML genes (Figure S12C, Table S4) such as TP53 (chr17p13.1, 8.5%), NF1 (chr17q11.2, 6.1%), or ETV6 (chr12p13.2, 5.3%, Figure S13). This evidence concerns the gene NF1 and acute myeloid leukemia.